

**Research Report**

Revised September 2017

# MDMA (Ecstasy) Abuse Research Report

---

## Table of Contents

MDMA (Ecstasy) Abuse Research Report

Introduction

What is MDMA?

What is the history of MDMA?

What is the scope of MDMA use in the United States?

Who is using MDMA?

What are the effects of MDMA?

What are MDMA's effects on the brain?

Can MDMA use during pregnancy harm the baby?

Is MDMA Addictive?

How can MDMA use be prevented?

How are MDMA use disorders treated?

References

# MDMA (Ecstasy) Abuse Research Report

Describes the science behind MDMA (ecstasy) abuse, including what it does to the brain, whether it is addictive, and the latest research regarding prevention and treatment of MDMA.

*This publication is available for your use and may be reproduced **in its entirety** without permission from NIDA. Citation of the source is appreciated, using the following language: Source: National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services.*

## Introduction


3,4-methylenedioxymethamphetamine (MDMA) continues to be used by millions of Americans across the country. This illegal drug is often taken for the feelings of well-being, stimulation, and distortions in time and sensory perceptions that it produces.<sup>1,2</sup> MDMA first became popular in the all-night party scene (e.g., “raves”),<sup>3</sup> but its use has now spread to a wide range of settings. According to the National Survey on Drug Use and Health, more than 18 million people in the United States have tried MDMA at least once in their lifetime.<sup>4</sup>

MDMA is a synthetic drug that became popular in the 1980s,<sup>5</sup> leading researchers to begin investigating its effects. Their efforts identified a number of potentially serious negative side effects. For example, MDMA can cause a dangerous increase in body temperature that can be fatal in some environments.<sup>6</sup>

MDMA can also stress the heart, increasing heart rate<sup>7</sup> and blood pressure,<sup>8</sup> and can damage the kidneys.<sup>9</sup> Animal studies show that MDMA may also damage specific neurons in the brain,<sup>10-12</sup> but research on MDMA’s effects on the human brain is not conclusive at this time.<sup>13</sup> However, a number of studies show that long-term, heavy MDMA use is associated with cognitive deficits, including problems with learning and memory.<sup>14</sup>

## What is MDMA?

MDMA is a synthetic drug that acts as a stimulant and hallucinogen.<sup>15-17</sup> It produces an energizing effect, distortions in time and perception, and enhanced enjoyment from sex. MDMA has also been described as an entactogen—a drug that can increase self-love.



Ecstasy is often used to refer to MDMA in the tablet or capsule form. Many people take the drug.<sup>17,19</sup> Researchers have determined that many people take MDMA at different concentrations, but also a number of other drugs or drug combinations that can be harmful. Adulterants found in ecstasy tablets purchased on the street have included methamphetamine, the anesthetic ketamine, caffeine, the diet drug ephedrine, the over-the-counter cough suppressant dextromethorphan,<sup>21,22</sup> heroin, phencyclidine (PCP), and cocaine.



@Shutterstock/SAHACHATZ

Some people mistakenly believe that using Molly can avoid contaminants often found in ecstasy, not realizing that drugs sold as Molly may not be MDMA.

Molly—slang for “molecular”—refers to the crystalline powder form of MDMA. It is usually sold as powder or in capsules. Some people mistakenly believe that Molly does not contain contaminants often found in ecstasy. In fact, chemical analyses of drugs sold as Molly and seized by the U.S. Drug Enforcement Administration (DEA) have shown that they often contain other types of

drugs and may not contain any MDMA. For example,

<sup>23</sup>

epidemiologists from Washington state and Florida reported in 2013 that substances being sold as Molly were actually methylone, a synthetic stimulant commonly found in “bath salts.”<sup>24</sup> In 2015, ethylone, a synthetic stimulant similar to methylone but with some differences in binding within the brain,<sup>25</sup> replaced methylone as the main substance marketed as Molly.<sup>26</sup> This underscores that people who take Molly often do not know what they are ingesting, and the substances sold as Molly may pose serious health risks.

When MDMA is taken in tablet or capsule form, a person begins feeling the effects 45 minutes later, on average. These effects peak 15 to 30 minutes after they are first felt and last an average of 3 hours,<sup>27</sup> though side effects could be experienced up to days later.<sup>17,28</sup> People typically take one to two tablets on each occasion,<sup>17,29,30</sup> with each tablet generally containing between 50 and 150 milligrams of MDMA.<sup>31</sup> People often take a second dose of the drug as the effects of the first dose begin to fade,<sup>32</sup> increasing the risk of adverse side effects as doses combine.

MDMA seized in the United States is primarily synthesized in Canada and, to a lesser extent, the Netherlands. There are a small number of illegal MDMA labs operating in the United States.<sup>19</sup>

## What is the history of MDMA?

MDMA was developed by a German pharmaceutical company in 1912. Originally known as “Methylsafrylaminc,” it was intended as a parent compound to synthesize medications that control bleeding, not to control appetite as is often incorrectly cited.<sup>33,34</sup>

MDMA gained a small following among psychiatrists in the late 1970s and early 1980s, despite the fact that the drug had not undergone formal clinical trials nor received approval from the U.S. Food and Drug Administration (FDA) for use in humans. Some psychiatrists believed that it enhanced communication in patient sessions and allowed patients to achieve insights about their problems.<sup>35</sup> It was also during this time that MDMA started becoming more widely available on the street.<sup>5,36</sup>

In 1985, the DEA declared an emergency ban on MDMA, placing it on the list of Schedule I drugs, defined as substances with no currently accepted medical use and a high potential for abuse. MDMA has remained a Schedule I substance since then, with the exception of a brief period of time between 1987 and 1988.<sup>37,38</sup>

## Does MDMA Have Therapeutic Value?

The evidence on MDMA’s therapeutic effects is limited thus far,<sup>39</sup> although research is ongoing in this area. Proponents of MDMA-assisted therapy recommend that it only be used for reactive

disorders such as post-traumatic stress disorder because it can worsen some psychiatric conditions.<sup>40</sup>

In the early 1990s, the FDA approved the first human trial exploring whether MDMA could help relieve pain in terminally ill patients, as well as serve as an adjunct to psychotherapy.<sup>41</sup> Results from this study have not been published; however, these early studies helped establish safety parameters for administering MDMA to human participants in controlled, clinical settings.<sup>42</sup> Clinical trials are ongoing to explore whether MDMA has therapeutic potential in the treatment of [post-traumatic stress disorder](#) and [anxiety](#) in autistic adults and patients with a terminal illness such as cancer.

## What is the scope of MDMA use in the United States?

*All data refer to the United States population.*

### How many people use MDMA (Ecstasy)?

- Among people aged 12 or older in 2020, 0.9% (or about 2.6 million people) reported using MDMA (Ecstasy) in the past 12 months.

Source: [2020 National Survey on Drug Use and Health](#)

### How many young people use MDMA?

- In 2021, an estimated 0.6% of 8<sup>th</sup> graders, 0.7% of 10<sup>th</sup> graders, and 1.1% of 12<sup>th</sup> graders reported using MDMA in the past 12 months.

Source: [2021 Monitoring the Future Survey](#)


## Who is using MDMA?

MDMA first gained popularity among adolescents and young adults in the nightclub scene and at dance parties known as raves.<sup>3</sup> However, the profile of the typical person who uses MDMA has been changing. Beginning in 1999, community-level data from NIDA's Community Epidemiology Work

Group began to report that use of MDMA had spread among populations outside the nightclub scene.<sup>49</sup>

MDMA is predominantly used by males between the ages of 18 and 25.<sup>43,50</sup> Most use typically begins at 21 years of age.<sup>51</sup>

NIDA-funded research shows that sexual orientation also influences use. Gay or bisexual men and women are more likely than their heterosexual counterparts to report MDMA use within the last 30 days and to report harm associated with use.<sup>52</sup>



## What are the effects of MDMA?

### Acute Effects

A person may experience the intoxicating effects of MDMA within 45 minutes or so after taking a single dose. Those effects include an enhanced sense of well-being,<sup>28,53</sup> increased extroversion,<sup>27,53</sup> emotional warmth, empathy toward others,<sup>54</sup> and a willingness to discuss emotionally-charged memories.<sup>55</sup> In addition, people report enhanced sensory perception as a hallmark of the MDMA experience.<sup>27,28</sup>



©Shutterstock.com/Radyukov Dima

Use of even moderate doses of MDMA in crowded, warm environments—or during periods of vigorous, extended physical activity—can dramatically

However, MDMA can also cause a number of acute adverse health effects. For example, while fatal overdoses on MDMA are rare, they can potentially be life threatening—with symptoms including high blood pressure (hypertension), faintness,<sup>8,56</sup> panic attacks,<sup>57</sup> and in severe cases, a loss of consciousness and seizures.<sup>58</sup> increase body temperature, with potential deadly consequences.

Because of its stimulant properties and the situations in which it is often taken, MDMA is associated with vigorous physical activity for extended periods in warm environments. This can lead to one of the most significant, although rare, acute adverse effects—a marked rise in body temperature (hyperthermia).<sup>59–61</sup> Research in rats shows that even moderate doses of MDMA interfere with the body's ability to regulate temperature, potentially leading to deadly consequences in warm environments.<sup>6</sup> Treatment of hyperthermia requires prompt medical attention, as it can rapidly lead to muscle breakdown or an electrolyte (sodium) imbalance, which can in turn produce kidney failure<sup>9</sup> or fatal swelling of the brain, especially in women.<sup>62</sup> MDMA use in combination with vigorous exercise causes dehydration,<sup>56,57</sup> leading some people to drink large amounts of liquids. However, this could increase the risk of electrolyte imbalance or brain swelling because MDMA causes the body to retain water.<sup>63,64</sup> One modest dose of MDMA can also reduce the pumping efficiency of the heart in people who use regularly,<sup>65</sup> which is of particular concern during periods of increased physical activity.

MDMA can also produce other adverse health effects, including involuntary jaw clenching,<sup>53</sup> lack of appetite,<sup>28,53</sup> mild detachment from oneself (depersonalization), illogical or disorganized thoughts, restless legs,<sup>28</sup> nausea,<sup>56,57,66</sup> hot flashes or chills,<sup>8,56</sup> headache, sweating,<sup>8,57</sup> and muscle or joint stiffness.<sup>66</sup>

In the hours after taking the drug, MDMA produces significant reductions in perceiving and predicting motion—for example, the ability to judge whether a driver is in danger of colliding with another car. This emphasizes the potential dangers of performing complex or skilled activities, such as driving a car, while under the influence of this drug.<sup>67</sup>

Once MDMA is metabolized, or broken down in the body, its byproducts interfere with the body's ability to metabolize MDMA.<sup>68</sup> As a result, additional doses of MDMA can produce unexpectedly high blood levels, which could worsen the toxic effects of this drug.<sup>69</sup> In addition, combining MDMA with other substances, such as caffeine,<sup>70</sup> amphetamines,<sup>71</sup> the amphetamine-like mephedrone,<sup>72</sup>

marijuana,<sup>73</sup> or alcohol,<sup>74,75</sup> may increase the risk of adverse health effects associated with MDMA.<sup>29</sup>

## Sub-acute Effects

Recreational use of MDMA is often characterized by repeated drug taking over a number of days (binges), followed by periods of no drug taking. In one animal study, this pattern of use produced irregular heartbeat (arrhythmia) and heart damage.<sup>76</sup> In the week following use of the drug, many people report depression, impaired attention and memory,<sup>77–79</sup> anxiety, aggression,<sup>80</sup> and irritability.<sup>78</sup>

## Effects of Regular MDMA Use

Sleep disturbances, lack of appetite, concentration difficulties, depression,<sup>79</sup> heart disease,<sup>81,82</sup> and impulsivity<sup>83</sup> have been associated with regular use of MDMA. In addition, heavy MDMA use over a 2-year period of time is associated with decreased cognitive function.<sup>84</sup> Some of these disturbances may not be directly attributable to MDMA, but may be related to some of the other drugs often used in combination with MDMA, such as cocaine, alcohol, or marijuana, or to adulterants commonly found in MDMA tablets. More research is needed to understand the specific effects of regular MDMA use.


## Risk-taking in People who Use MDMA

Various studies have found that MDMA use is associated with risky sexual behaviors. For example, both males and females who use MDMA are more likely than alcohol-drinking controls to engage in risky sexual behaviors (e.g., without a condom).<sup>85</sup> MDMA use within the past 6 months is associated with initiating sex before age 14 and having two or more partners in the past 2 months.<sup>86</sup> In addition, people who use heavily report more sexual risk taking than those who use less often. People who use heavily are also more likely to have been tested for HIV, though they believe they are at low risk for contracting the disease.<sup>87</sup>

Homosexuals and bisexuals who use MDMA, both male and female, reported more sexual partners and more injection drug use—but did not have higher rates of unprotected sex and needle sharing—compared to heterosexuals who use MDMA.<sup>88</sup>



# What are MDMA's effects on the brain?



## MDMA's Effects on Serotonin, Dopamine and Norepinephrine.

MDMA increases levels of these neurotransmitters within the synapse by enhancing their release from nerve endings and/or inhibiting their reuptake.


MDMA affects the brain by increasing the activity of at least three neurotransmitters (the chemical messengers

of brain cells): serotonin, dopamine, and

norepinephrine.<sup>91</sup> Like other amphetamines, MDMA enhances release of these neurotransmitters<sup>89,90</sup> and/or blocks their reuptake,<sup>93,94</sup> resulting in increased neurotransmitter levels within the synaptic cleft (the space between the neurons at a synapse).<sup>89-92</sup>

MDMA causes greater release of serotonin and norepinephrine than of dopamine.<sup>91</sup> Serotonin is a neurotransmitter that plays an important role in the regulation of mood, sleep, pain, appetite, and other behaviors. The excess release of serotonin by MDMA likely causes the mood-elevating effects people experience.

However, by releasing large amounts of serotonin, MDMA causes the brain to become significantly depleted of this important neurotransmitter, contributing to the negative psychological aftereffects that people may experience for several days after taking MDMA.<sup>95,96</sup>



Research in rodents and primates has shown that moderate to high doses of MDMA, given twice daily for four days, damages nerve cells that contain serotonin.

<sup>10,12</sup> MDMA-exposed primates showed reduced numbers of serotonergic neurons 7 years later, indicating that some of MDMA's effect on the brain can be long lasting.<sup>11</sup> MDMA has additional effects on the serotonin system. For example, 1 to 2 weeks following binge-dosing with MDMA (three or four low doses in one day), rats showed decreased expression of the serotonin transporter,<sup>13,97</sup> a protein that allows cells to take up and recycle released serotonin. The rats also showed changes in the expression of genes that regulate tryptophan hydroxylase, an enzyme involved in serotonin synthesis.

Low serotonin is associated with poor memory and depressed mood,<sup>98</sup> thus these findings are consistent with studies in humans that have shown that some people who use MDMA regularly experience confusion,<sup>30</sup> depression,<sup>30,99</sup> anxiety, paranoia,<sup>30,100</sup> and impairment of memory<sup>83,101,102</sup> and attention processes.<sup>79</sup> In addition, studies have found that the extent of MDMA use in humans correlates with a decrease in serotonin metabolites and other markers of serotonin function and the degree of memory impairment.<sup>95,101</sup> In addition, MDMA's effects on norepinephrine contribute to the cognitive impairment,<sup>94</sup> emotional excitation, and euphoria that accompanies MDMA use.<sup>7</sup>

Positron emission tomography (PET) brain imaging studies of people who have stopped using MDMA have shown decreases in brain activity at rest in prefrontal, parietal, and mediotemporal cortices as well as in the amygdala, cingulate, and hippocampus. These are brain regions involved in learning, memory, and emotion formation and processing.<sup>103,104</sup> PET imaging also showed that one low dose of MDMA increased cerebral blood in the ventromedial frontal and occipital cortex and inferior temporal lobe and cerebellum. It decreased cerebral blood flow in the motor and somatosensory cortex, amygdala, cingulate cortex, insula, and thalamus. These are brain regions involved in emotion formation and processing, behavioral learning, and sensory and motor function.<sup>53</sup> Few imaging studies have explored the effects of moderate MDMA use on the human brain, and results that do exist are inconsistent due to methodological differences across studies.<sup>105</sup> More studies are needed to determine whether the observed changes in brain activity in people who use MDMA are caused by MDMA, other drug use, or other common risk factors that predispose people to use MDMA.

Source: Hatzidimitriou G, et al. J Neurosci Off J Soc Neurosci. 1999

Reduced Serotonin in Cerebral Cortex Neurons Following Long-term MDMA

MDMA's effect on the brain can be long lasting. The left panel is brain tissue from a normal monkey. The middle and right panels illustrate the loss of serotonin-containing nerve endings following MDMA exposure.

Additionally, most studies in people do not have behavioral measures from before MDMA use started, making it difficult to rule out pre-existing differences or common underlying risk factors across groups that are separate from MDMA use.<sup>83,106,107</sup> Factors such as gender, dosage, frequency and intensity of use, age at which use began, and the use of other drugs, as well as genetic and environmental factors all may play a role in some of the cognitive deficits associated with MDMA use and should be taken into consideration when studying the effects of MDMA in humans.

## Effects of MDMA

### Potential Acute Adverse Health Effects:

- Marked rise in body temperature (hyperthermia)
- Dehydration
- Electrolyte (sodium) imbalance
- High blood pressure (hypertension)
- Involuntary jaw clenching and teeth grinding
- Muscle or joint stiffness
- Lack of appetite
- Illogical or disorganized thoughts
- Restless legs
- Nausea
- Hot flashes or chills
- Headache
- Sweating
- Faintness
- Panic attacks
- Loss of consciousness
- Seizures

- Kidney failure
- Swelling of the brain

### Potential Longer Term Health Effects (including those observed days or weeks post-MDMA use):

- Arrhythmia (irregular heart beat) and heart damage
- Irritability
- Depression
- Impulsivity
- Impaired attention and memory
- Anxiety
- Aggression
- Sleep disturbances
- Concentration difficulties
- Lack of appetite
- Heart disease
- Decreased cognitive function

## Can MDMA use during pregnancy harm the baby?

Given that most people who use MDMA are young and in their reproductive years,<sup>50</sup> some females may use MDMA when pregnant. Research suggests that MDMA may have adverse effects on the developing fetus. One study in humans showed that prenatal MDMA exposure was associated with motor delays in the offspring up to 2 years after birth. More research is needed to determine if these delays persist later in life.<sup>108</sup> Behavioral studies in animals have found significant adverse effects on tests of learning and memory following exposure to MDMA during a developmental period equivalent to the latter portion of the third trimester in humans.<sup>109</sup> These changes are paralleled by long-lasting changes in brain regions underlying learning and memory.<sup>110</sup> There is less research into the effects of

MDMA on animals earlier in development—that is, during the period equivalent to the first trimester in humans.<sup>109,111</sup> One study showed that MDMA exposure during this developmental period produces increased motor activity and changes in serotonin and dopamine function in rodents.<sup>112</sup> In addition, rats prenatally exposed to MDMA and alcohol showed decreased exploratory activity, impaired working memory, and impaired neuronal development into adulthood, although the contribution of MDMA alone was not determined.<sup>113</sup>

## Is MDMA Addictive?

Research hasn't definitively answered whether MDMA is addictive, although it affects many of the same neurotransmitter systems in the brain that are targeted by other addictive drugs. Experiments have shown that animals will self-administer MDMA—an important indicator of a drug's addictive potential—although the degree of self-administration is less than some other addictive drugs, such as cocaine.<sup>114,115</sup>

Data from both humans and animals suggest that regular MDMA use produces adaptations in the serotonin and dopamine systems that are associated with substance use disorder and related behaviors, such as increased impulsivity.<sup>116</sup> Few studies have attempted to assess MDMA addiction or dependency among people with a history of use in the general population. Studies that have been conducted have shown widely varying results, likely because of the different population samples and different types of measures used. Some people who use MDMA do report symptoms of addiction, including continued use despite negative physical or psychological consequences, tolerance, withdrawal,<sup>117,118</sup> and craving.<sup>119</sup>

## How can MDMA use be prevented?

Providing accurate scientific information regarding the effects of MDMA is important for reducing the negative health effects associated with use of this drug. Young adults who use MDMA report that friends, substance use disorder treatment programs, and physicians are their most trusted sources of information about MDMA. Many also report that the internet is an important source of information, suggesting that prevention websites should be designed to be responsive to the needs of this

population.<sup>120</sup> In addition, the use of peer-led advocacy and drug prevention programs may be a promising approach to reduce MDMA use among adolescents and young adults.

New technologies could also help in delivering messages to high school and college students about the effects of MDMA use. For example, one study showed that an online school-based prevention program reduced students' intentions to use MDMA and other drugs.<sup>121</sup>

More information on preventing drug use among children and teens can be found in NIDA's [Preventing Drug Use among Children and Adolescents \(In Brief\)](#).

## How are MDMA use disorders treated?

The most effective current treatments for patients with an MDMA use disorder are cognitive behavioral interventions that are designed to help modify the patient's thinking, expectancies, and behaviors, and to increase skills in coping with life's stressors. Recovery support groups may be effective in combination with behavioral interventions to support long-term recovery.

Although there are currently a number of medication targets that show promise in animal models<sup>122-124</sup> and in some early clinical trials,<sup>125,126</sup> there are currently no FDA-approved medications to treat MDMA use disorder.



@iStock/vadimguzhva

Cognitive Behavioral Therapy helps patients recognize, avoid, and cope with the situations in which they are most likely to abuse drugs.

## References

1. Hermle L, Spitzer M, Borchardt D, Kovar KA, Gouzoulis E. Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? *Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol*. 1993;8(2):171-176. doi:10.1038/npp.1993.19.

2. Vollenweider FX. Brain mechanisms of hallucinogens and entactogens. *Dialogues Clin Neurosci*. 2001;3(4):265-279.
3. Schwartz RH, Miller NS. MDMA (ecstasy) and the rave: a review. *Pediatrics*. 1997;100(4):705-708.
4. SAMHSA. *Results from the 2016 National Survey on Drug Use and Health: Detailed Tables*. Rockville (MD): SAMHSA; 2017. <https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf>.
5. Passie T, Benzenhöfer U. The History of MDMA as an Underground Drug in the United States, 1960–1979. *J Psychoactive Drugs*. 2016;48(2):67-75. doi:10.1080/02791072.2015.1128580.
6. Kiyatkin EA, Kim AH, Wakabayashi KT, Baumann MH, Shaham Y. Critical role of peripheral vasoconstriction in fatal brain hyperthermia induced by MDMA (Ecstasy) under conditions that mimic human drug use. *J Neurosci Off J Soc Neurosci*. 2014;34(23):7754-7762. doi:10.1523/JNEUROSCI.0506-14.2014.
7. Hysek CM, Simmler LD, Ineichen M, et al. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans. *Clin Pharmacol Ther*. 2011;90(2):246-255. doi:10.1038/clpt.2011.78.
8. Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. *Psychopharmacology (Berl)*. 2002;162(4):396-405. doi:10.1007/s00213-002-1131-1.
9. Campbell GA, Rosner MH. The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. *Clin J Am Soc Nephrol CJASN*. 2008;3(6):1852-1860. doi:10.2215/CJN.02080508.
10. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. *J Pharmacol Exp Ther*. 1987;241(1):338-345.
11. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. *J Neurosci Off J Soc Neurosci*. 1999;19(12):5096-5107.
12. O’Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. *J Neurosci Off J Soc Neurosci*. 1988;8(8):2788-2803.
13. Biezonski DK, Meyer JS. The Nature of 3, 4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonergic Dysfunction: Evidence for and Against the Neurodegeneration Hypothesis. *Curr*



*Neuropharmacol.* 2011;9(1):84-90. doi:10.2174/157015911795017146.

14. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). *J Neurol Neurosurg Psychiatry.* 2000;68(6):719-725.
15. Gold LH, Koob GF, Geyer MA. Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. *J Pharmacol Exp Ther.* 1988;247(2):547-555.
16. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. *Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol.* 1988;1(4):273-277.
17. Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of "Ecstasy" users and their experiences with the drug. *Br J Addict.* 1992;87(8):1161-1172.
18. EMCDDA. MDMA ("Ecstasy") drug profile. January 2015.  
<http://www.emcdda.europa.eu/publications/drug-profiles/mdma>.
19. DEA. Drugs of Abuse. 2015 Edition: A DEA Resource Guide. 2015.  
[http://www.dea.gov/pr/multimedia-library/publications/drug\\_of\\_abuse.pdf#page=62](http://www.dea.gov/pr/multimedia-library/publications/drug_of_abuse.pdf#page=62).
20. Sherlock K, Wolff K, Hay AW, Conner M. Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. *J Accid Emerg Med.* 1999;16(3):194-197.
21. Baggott M, Heifets B, Jones R, Mendelson J, Sferios E, Zehnder J. Chemical analysis of ecstasy pills. *J Am Med Assoc.* 2000;284(17):2190.
22. Tanner-Smith EE. Pharmacological content of tablets sold as "ecstasy": results from an online testing service. *Drug Alcohol Depend.* 2006;83(3):247-254. doi:10.1016/j.drugalcdep.2005.11.016.
23. DEA. Microgram Bulletin. December 2008. Accessed September 19, 2016.
24. Community Epidemiology Work Group. *Proceedings of the Community Epidemiology Work Group.* NIDA; 2014. <https://archives.drugabuse.gov/sites/default/files/cewgjune2014.pdf>.
25. Simmler LD, Buser TA, Donzelli M, et al. Pharmacological characterization of designer cathinones in vitro. *Br J Pharmacol.* 2013;168(2):458-470. doi:10.1111/j.1476-5381.2012.02145.x.
26. NDEWS. *NDEWS News.*; 2015.  
[https://ndews.umd.edu/sites/ndews.umd.edu/files/ndews\\_news\\_issue-1\\_august\\_2015\\_final.pdf](https://ndews.umd.edu/sites/ndews.umd.edu/files/ndews_news_issue-1_august_2015_final.pdf).
27. Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. *Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol.*



2000;22(5):513-521. doi:10.1016/S0893-133X(99)00148-7.

28. Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers. *Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol*. 1998;19(4):241-251. doi:10.1016/S0893-133X(98)00013-X.
29. Scholey AB, Parrott AC, Buchanan T, Heffernan TM, Ling J, Rodgers J. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study. *Addict Behav*. 2004;29(4):743-752. doi:10.1016/j.addbeh.2004.02.022.
30. Topp L, Hando J, Dillon P, Roche A, Solowij N. Ecstasy use in Australia: patterns of use and associated harm. *Drug Alcohol Depend*. 1999;55(1-2):105-115.
31. DEA. Drug Fact Sheet: Ecstasy or MDMA. <https://www.dea.gov/factsheets/ecstasy-or-mdma-also-known-molly>. Accessed February 25, 2016.
32. Parrott AC. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. *J Psychopharmacol Oxf Engl*. 2005;19(1):71-83. doi:10.1177/0269881105048900.
33. Bernschneider-Reif S, Oxler F, Freudenmann RW. The origin of MDMA ("ecstasy")--separating the facts from the myth. *Pharm*. 2006;61(11):966-972.
34. Freudenmann RW, Oxler F, Bernschneider-Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. *Addict Abingdon Engl*. 2006;101(9):1241-1245. doi:10.1111/j.1360-0443.2006.01511.x.
35. Grinspoon L, Bakalar JB. Can drugs be used to enhance the psychotherapeutic process? *Am J Psychother*. 1986;40(3):393-404.
36. Parrott AC. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. *Hum Psychopharmacol*. 2001;16(8):557-577. doi:10.1002/hup.351.
37. DEA. Schedules of Controlled Substances; Scheduling of 3,4-Methylenedioxymethamphetamine (MDMA) into Schedule I of the Controlled Substances Act; Remand. 1988;53(34):5156.
38. DEA. Orangebook. Lists of: Scheduling Actions Controlled Substances Regulated Chemicals. November 2015. <http://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf>.
39. White CM. 3,4-Methylenedioxymethamphetamine's (MDMA's) Impact on Posttraumatic Stress Disorder. *Ann Pharmacother*. 2014;48(7):908-915. doi:10.1177/1060028014532236.
40. Parrott AC. The potential dangers of using MDMA for psychotherapy. *J Psychoactive Drugs*. 2014;46(1):37-43. doi:10.1080/02791072.2014.873690.

41. Grob C. MDMA research: preliminary investigations with human subjects. *Int J Drug Policy*. 1998;9(2):119-124.
42. Grob CS, Poland RE, Chang L, Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. *Behav Brain Res*. 1996;73(1-2):103-107.
43. SAMHSA. *National Survey on Drug Use and Health, 2002-2014*. Rockville, MD: SAMHSA; 2015. <https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs2014/NSDUH-DetTabs2014.pdf>.
44. SAMHSA. *Results from the 2004 National Survey on Drug Use and Health: National Findings*. Rockville, MD: SAMHSA; 2005. <http://archive.samhsa.gov/data/NSDUH/2k4nsduh/2k4results/2k4results.pdf>.
45. Johnston L, O'Malley P, Miech R, Bachman J, Schulenberg J. *Monitoring the Future National Survey Results on Drug Use, 1975-2016: Overview, Key Findings on Adolescent Drug Use*. Ann Arbor: Institute for Social Research, The University of Michigan; 2017.
46. Palamar JJ, Kamboukos D. An examination of sociodemographic correlates of ecstasy use among high school seniors in the United States. *Subst Use Misuse*. 2014;49(13):1774-1783. doi:10.3109/10826084.2014.926933.
47. SAMHSA. *Drug Abuse Warning Network, 2011: Selected Tables of National Estimates of Drug-Related Emergency Department Visits*. Rockville, MD: SAMHSA; 2013. [http://www.samhsa.gov/data/sites/default/files/Nation\\_2011\\_Illicit.xls](http://www.samhsa.gov/data/sites/default/files/Nation_2011_Illicit.xls).
48. SAMHSA. *Treatment Episode Data Set (TEDS): 2004-2014. National Admissions to Substance Abuse Treatment Services*. Rockville, MD; 2016. [https://www.dasis.samhsa.gov/dasis2/teds\\_pubs/2014\\_teds\\_rpt\\_natl.pdf](https://www.dasis.samhsa.gov/dasis2/teds_pubs/2014_teds_rpt_natl.pdf).
49. Community Epidemiology Work Group. *Epidemiologic Trends in Drug Abuse, Volume 1: Highlights and Executive Summary*. NIDA; 1999. <https://archives.drugabuse.gov/sites/default/files/cewg1299.pdf>.
50. SAMHSA. *Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health*. SAMHSA; 2015. <http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.htm#idtextanchor030>.
51. SAMHSA. *Risk and Protective Factors and Initiation of Substance Use: Results from the 2014 National Survey on Drug Use and Health*. Rockville, MD: SAMHSA; 2015. <https://www.samhsa.gov/data/sites/default/files/NSDUH-DR-FRR4-2014rev/NSDUH-DR-FRR4-2014.pdf>.

52. Chow C, Vallance K, Stockwell T, et al. Sexual identity and drug use harm among high-risk, active substance users. *Cult Health Sex*. 2013;15(3):311-326. doi:10.1080/13691058.2012.754054.
53. Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX, Hell D. 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [<sup>18</sup>F]-PET in healthy humans. *Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol*. 2000;23(4):388-395. doi:10.1016/S0893-133X(00)00130-5.
54. Hysek CM, Schmid Y, Simmler LD, et al. MDMA enhances emotional empathy and prosocial behavior. *Soc Cogn Affect Neurosci*. 2014;9(11):1645-1652. doi:10.1093/scan/nst161.
55. Baggott MJ, Coyle JR, Siegrist JD, Garrison KJ, Galloway GP, Mendelson JE. Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. *J Psychopharmacol Oxf Engl*. February 2016. doi:10.1177/0269881115626348.
56. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. *Psychopharmacology (Berl)*. 2001;154(2):161-168.
57. Davison D, Parrott AC. Ecstasy (MDMA) in Recreational Users: Self-Reported Psychological and Physiological Effects. *Hum Psychopharmacol Clin Exp*. 1997;12:221-226.
58. Le Roux G, Bruneau C, Lelièvre B, et al. Recreational phenethylamine poisonings reported to a French poison control center. *Drug Alcohol Depend*. 2015;154:46-53. doi:10.1016/j.drugalcdep.2015.05.048.
59. Armenian P, Mamantov TM, Tsutaoka BT, et al. Multiple MDMA (Ecstasy) overdoses at a rave event: a case series. *J Intensive Care Med*. 2013;28(4):252-258. doi:10.1177/0885066612445982.
60. Dafters RI, Lynch E. Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy") but not by fenfluramine. *Psychopharmacology (Berl)*. 1998;138(2):207-212.
61. Ridpath A, Driver CR, Nolan ML, et al. Illnesses and deaths among persons attending an electronic dance-music festival - New York City, 2013. *MMWR Morb Mortal Wkly Rep*. 2014;63(50):1195-1198.
62. Moritz ML, Kalantar-Zadeh K, Ayus JC. Ecstasy-associated hyponatremia: why are women at risk? *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc*. 2013;28(9):2206-2209. doi:10.1093/ndt/gft192.
63. Baggott MJ, Garrison KJ, Coyle JR, et al. MDMA Impairs Response to Water Intake in Healthy Volunteers. *Adv Pharmacol Sci*. 2016;2016:2175896. doi:10.1155/2016/2175896.

64. van Dijken GD, Blom RE, Hené RJ, Boer WH, NIGRAM Consortium null. High incidence of mild hyponatraemia in females using ecstasy at a rave party. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc.* 2013;28(9):2277-2283. doi:10.1093/ndt/gft023.
65. Lester SJ, Baggott M, Welm S, et al. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. *Ann Intern Med.* 2000;133(12):969-973.
66. Cohen RS. Subjective reports on the effects of the MDMA ('ecstasy') experience in humans. *Prog Neuropsychopharmacol Biol Psychiatry.* 1995;19(7):1137-1145.
67. Lamers CTJ, Ramaekers JG, Muntjewerff ND, et al. Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. *J Psychopharmacol Oxf Engl.* 2003;17(4):379-387.
68. Concheiro M, Baumann MH, Scheidweiler KB, Rothman RB, Marrone GF, Huestis MA. Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. *Drug Metab Dispos Biol Fate Chem.* 2014;42(1):119-125. doi:10.1124/dmd.113.053678.
69. da Silva DD, Silva E, Carvalho F, Carmo H. Mixtures of 3,4-methylenedioxymethamphetamine (ecstasy) and its major human metabolites act additively to induce significant toxicity to liver cells when combined at low, non-cytotoxic concentrations. *J Appl Toxicol JAT.* 2014;34(6):618-627. doi:10.1002/jat.2885.
70. Camarasa J, Pubill D, Escubedo E. Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug. *Brain Res.* 2006;1111(1):72-82. doi:10.1016/j.brainres.2006.06.087.
71. Dias da Silva D, Carmo H, Silva E. The risky cocktail: what combination effects can we expect between ecstasy and other amphetamines? *Arch Toxicol.* 2013;87(1):111-122. doi:10.1007/s00204-012-0929-9.
72. Angoa-Pérez M, Kane M, Briggs D, et al. Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. *J Neurochem.* 2013;125(1):102-110.
73. Dumont GJ, Kramers C, Sweep FC, et al. Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans. *Clin Pharmacol Ther.* 2009;86(2):160-166. doi:10.1038/clpt.2009.62.
74. Navarro-Zaragoza J, Ros-Simó C, Milanés M-V, Valverde O, Laorden M-L. Binge Ethanol and MDMA Combination Exacerbates Toxic Cardiac Effects by Inducing Cellular Stress. *PLoS One.*

2015;10(10):e0141502. doi:10.1371/journal.pone.0141502.

75. Ros-Simó C, Ruiz-Medina J, Valverde O. Behavioural and neuroinflammatory effects of the combination of binge ethanol and MDMA in mice. *Psychopharmacology (Berl)*. 2012;221(3):511-525. doi:10.1007/s00213-011-2598-4.
76. Badon LA, Hicks A, Lord K, Ogden BA, Meleg-Smith S, Varner KJ. Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of Ecstasy. *J Pharmacol Exp Ther*. 2002;302(3):898-907.
77. Curran HV, Travill RA. Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): week-end "high" followed by mid-week low. *Addict Abingdon Engl*. 1997;92(7):821-831.
78. Parrott AC, Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. *Psychopharmacology (Berl)*. 1998;139(3):261-268.
79. Verheyden SL, Henry JA, Curran HV. Acute, sub-acute and long-term subjective consequences of "ecstasy" (MDMA) consumption in 430 regular users. *Hum Psychopharmacol*. 2003;18(7):507-517. doi:10.1002/hup.529.
80. Verheyden SL, Hadfield J, Calin T, Curran HV. Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, "ecstasy") on mood: evidence of gender differences. *Psychopharmacology (Berl)*. 2002;161(1):23-31. doi:10.1007/s00213-001-0995-9.
81. Droogmans S, Cosyns B, D'haenen H, et al. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. *Am J Cardiol*. 2007;100(9):1442-1445. doi:10.1016/j.amjcard.2007.06.045.
82. Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. *Mol Pharmacol*. 2003;63(6):1223-1229. doi:10.1124/mol.63.6.1223.
83. Morgan MJ. Memory deficits associated with recreational use of "ecstasy" (MDMA). *Psychopharmacology (Berl)*. 1999;141(1):30-36.
84. Wagner D, Tkotz S, Koester P, Becker B, Gouzoulis-Mayfrank E, Daumann J. Learning, Memory, and Executive Function in New MDMA Users: A 2-Year Follow-Up Study. *Front Neurosci*. 2015;9:445. doi:10.3389/fnins.2015.00445.
85. May AL, Parrott AC. Greater sexual risk-taking in female and male recreational MDMA/ecstasy users compared with alcohol drinkers: a questionnaire study. *Hum Psychopharmacol*. 2015;30(4):272-275. doi:10.1002/hup.2432.

86. Novoa RA, Ompad DC, Wu Y, Vlahov D, Galea S. Ecstasy use and its association with sexual behaviors among drug users in New York City. *J Community Health*. 2005;30(5):331-343.
87. Theall KP, Elifson KW, Sterk CE. Sex, touch, and HIV risk among ecstasy users. *AIDS Behav*. 2006;10(2):169-178. doi:10.1007/s10461-005-9059-1.
88. Degenhardt L. Drug use and risk behaviour among regular ecstasy users: Does sexuality make a difference? *Cult Health Sex*. 2005;7(6):599-614. doi:10.1080/13691050500349875.
89. Gough B, Ali SF, Slikker W, Holson RR. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. *Pharmacol Biochem Behav*. 1991;39(3):619-623.
90. Schmidt CJ, Levin JA, Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. *Biochem Pharmacol*. 1987;36(5):747-755.
91. Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. *Synapse N Y N*. 2001;39(1):32-41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3.
92. Sabol KE, Seiden LS. Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis. *Brain Res*. 1998;806(1):69-78.
93. Berger UV, Gu XF, Azmitia EC. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. *Eur J Pharmacol*. 1992;215(2-3):153-160.
94. Verrico CD, Lynch L, Fahey MA, Fryer A-K, Miller GM, Madras BK. MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor. *J Psychopharmacol Oxf Engl*. 2008;22(2):187-202. doi:10.1177/0269881107083639.
95. Bolla KI, McCann UD, Ricourte GA. Memory impairment in abstinent MDMA ("Ecstasy") users. *Neurology*. 1998;51(6):1532-1537.
96. Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS. Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. *Neurology*. 2000;55(2):294-296.
97. Cuyas E, Robledo P, Pizarro N, et al. 3,4-methylenedioxymethamphetamine induces gene expression changes in rats related to serotonergic and dopaminergic systems, but not to neurotoxicity. *Neurotox Res*. 2014;25(2):161-169. doi:10.1007/s12640-013-9416-1.

98. Jenkins TA, Nguyen JCD, Polglaze KE, Bertrand PP. Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. *Nutrients*. 2016;8(1). doi:10.3390/nu8010056.
99. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R. MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. *Drug Alcohol Depend*. 1998;52(1):85-90.
100. Parrott AC, Sisk E, Turner JJ. Psychobiological problems in heavy "ecstasy" (MDMA) polydrug users. *Drug Alcohol Depend*. 2000;60(1):105-110.
101. Verkes RJ, Gijsman HJ, Pieters MS, et al. Cognitive performance and serotonergic function in users of ecstasy. *Psychopharmacology (Berl)*. 2001;153(2):196-202.
102. Wareing M, Fisk JE, Murphy PN. Working memory deficits in current and previous users of MDMA ('ecstasy'). *Br J Psychol Lond Engl 1953*. 2000;91 ( Pt 2):181-188.
103. Bosch OG, Wagner M, Jessen F, et al. Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users. *PloS One*. 2013;8(4):e61234. doi:10.1371/journal.pone.0061234.
104. Obrocki J, Buchert R, Väterlein O, Thomasius R, Beyer W, Schiemann T. Ecstasylong-term effects on the human central nervous system revealed by positron emission tomography. *Br J Psychiatry J Ment Sci*. 1999;175:186-188.
105. Mueller F, Lenz C, Steiner M, et al. Neuroimaging in moderate MDMA use: A systematic review. *Neurosci Biobehav Rev*. 2015;62:21-34. doi:10.1016/j.neubiorev.2015.12.010.
106. Kish SJ. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? *Pharmacol Biochem Behav*. 2002;71(4):845-855.
107. Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen H. Mental disorders in ecstasy users: a prospective-longitudinal investigation. *Drug Alcohol Depend*. 2002;68(2):195-207.
108. Singer LT, Moore DG, Min MO, et al. Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK. *Hum Psychopharmacol*. 2015;30(4):290-294. doi:10.1002/hup.2459.
109. Broening HW, Morford LL, Inman-Wood SL, Fukumura M, Vorhees CV. 3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. *J Neurosci Off J Soc Neurosci*. 2001;21(9):3228-3235.
110. Williams MT, Skelton MR, Longacre ID, et al. Neuronal reorganization in adult rats neonatally exposed to (±)-3,4-methylenedioxymethamphetamine. *Toxicol Rep*. 2014;1:699-706.

doi:10.1016/j.toxrep.2014.08.018.

111. Colado MI, O'Shea E, Granados R, Misra A, Murray TK, Green AR. A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. *Br J Pharmacol.* 1997;121(4):827-833. doi:10.1038/sj.bjp.0701201.
112. Koprlich JB, Chen E-Y, Kanaan NM, Campbell NG, Kordower JH, Lipton JW. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. *Neurotoxicol Teratol.* 2003;25(5):509-517.
113. Canales JJ, Ferrer-Donato A. Prenatal exposure to alcohol and 3,4-methylenedioxymethamphetamine (ecstasy) alters adult hippocampal neurogenesis and causes enduring memory deficits. *Dev Neurosci.* 2014;36(1):10-17. doi:10.1159/000356820.
114. Degenhardt L, Bruno R, Topp L. Is ecstasy a drug of dependence? *Drug Alcohol Depend.* 2010;107(1):1-10. doi:10.1016/j.drugalcdep.2009.09.009.
115. Schenk S, Hely L, Lake B, Daniela E, Gittings D, Mash DC. MDMA self-administration in rats: acquisition, progressive ratio responding and serotonin transporter binding. *Eur J Neurosci.* 2007;26(11):3229-3236. doi:10.1111/j.1460-9568.2007.05932.x.
116. Schenk S, Aronsen D. Contribution of Impulsivity and Serotonin Receptor Neuroadaptations to the Development of an MDMA ('Ecstasy') Substance Use Disorder. *Curr Top Behav Neurosci.* December 2015. doi:10.1007/7854\_2015\_421.
117. Cottler LB, Leung KS, Abdallah AB. Test-re-test reliability of DSM-IV adopted criteria for 3,4-methylenedioxymethamphetamine (MDMA) abuse and dependence: a cross-national study. *Addict Abingdon Engl.* 2009;104(10):1679-1690. doi:10.1111/j.1360-0443.2009.02649.x.
118. Cottler LB, Womack SB, Compton WM, Ben-Abdallah A. Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. *Hum Psychopharmacol.* 2001;16(8):599-606. doi:10.1002/hup.343.
119. Davis AK, Rosenberg H. The prevalence, intensity, and assessment of craving for MDMA/ecstasy in recreational users. *J Psychoactive Drugs.* 2014;46(2):154-161. doi:10.1080/02791072.2014.901586.
120. Falck RS, Carlson RG, Wang J, Siegal HA. Sources of information about MDMA (3,4-methylenedioxymethamphetamine): perceived accuracy, importance, and implications for prevention among young adult users. *Drug Alcohol Depend.* 2004;74(1):45-54. doi:10.1016/j.drugalcdep.2003.11.009.



121. Champion KE, Newton NC, Stapinski LA, Teesson M. Effectiveness of a universal Internet-based prevention program for ecstasy and new psychoactive substances: a cluster randomised controlled trial. *Addict Abingdon Engl*. February 2016. doi:10.1111/add.13345.
122. Ciudad-Roberts A, Camarasa J, Pubill D, Escubedo E. Heteromeric nicotinic receptors are involved in the sensitization and addictive properties of MDMA in mice. *Prog Neuropsychopharmacol Biol Psychiatry*. 2013;44:201-209. doi:10.1016/j.pnpbp.2013.02.013.
123. Rodríguez-Arias M, Valverde O, Daza-Losada M, Blanco-Gandía MC, Aguilar MA, Miñarro J. Assessment of the abuse potential of MDMA in the conditioned place preference paradigm: role of CB1 receptors. *Prog Neuropsychopharmacol Biol Psychiatry*. 2013;47:77-84. doi:10.1016/j.pnpbp.2013.07.013.
124. Roger-Sánchez C, Rodríguez-Arias M, Miñarro J, Aguilar MA. Involvement of 5-hydroxytryptamine 5-HT<sub>2</sub> serotonergic receptors in the acquisition and reinstatement of the conditioned place preference induced by MDMA. *Eur J Pharmacol*. 2013;714(1-3):132-141. doi:10.1016/j.ejphar.2013.06.005.
125. Hysek CM, Simmler LD, Nicola VG, et al. Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. *PloS One*. 2012;7(5):e36476. doi:10.1371/journal.pone.0036476.
126. Hysek CM, Fink AE, Simmler LD, Donzelli M, Grouzmann E, Liechti ME.  $\alpha$ -Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans. *J Clin Psychopharmacol*. 2013;33(5):658-666. doi:10.1097/JCP.0b013e3182979d32.